3,5-二氯-N-甲基苄胺盐酸盐 | 90390-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯-N-甲基苄胺盐酸盐
• 英文名称: N-methyl-3,5-dichlorobenzylamine
• 英文别名: N-Methyl-3,5-dichlor-benzylamin；N-methyl-N-(3,5-dichlorobenzyl)amine；3,5-dichlorobenzyl-methyl amine；3,5-dichloro-N-methylbenzylamine；1-(3,5-dichlorophenyl)-N-methylmethanamine
• CAS: 90390-21-9
• 化学式: C₈H₉Cl₂N
• mdl: MFCD00196813
• 分子量: 190.072
• InChiKey: SSTJQZMMDIIKBR-UHFFFAOYSA-N

物化性质

• 沸点：
  240.6±25.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P330,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  1760
• 危险性描述：
  H302,H315,H318,H335

反应信息

• 作为反应物：
  描述：

  3,5-二氯-N-甲基苄胺盐酸盐 在 potassium carbonate 、 lithium hexamethyldisilazane 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成
  参考文献：
  名称：

  Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis

  摘要：

  Pyrazolone derivatives have previously been found to be inhibitors of Cu/Zn superoxide dismutase 1 (S OD 1) - dep en dent protein aggregation, which extended survival of an amyotrophic lateral sclerosis (ALS) mouse model. On the basis of ADME analysis, we describe herein a new series of tertiary amine-containing pyrazolones and their structure activity relationships. Further conversion to the conjugate salts greatly improved their solubility. Phosphate compound 17 exhibited numerous benefits both to cellular activity and to CNS-related drug-like properties in vitro and in vivo, including microsomal stability, tolerated toxicity, and blood brain barrier permeation. These results indicate that tertiary amine pyrazolones comprise a valuable class of ALS drug candidates.

  DOI：

  10.1021/acs.jmedchem.5b00561
• 作为产物：
  描述：

  3,5-二氯苯甲醛 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 3,5-二氯-N-甲基苄胺盐酸盐
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：NOVIRA THERAPEUTICS INC

  公开号：WO2013096744A1

  公开（公告）日：2013-06-27

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种抑制、压制或预防需要的人体内HBV感染的方法，包括向个体投给治疗有效量的至少一种本发明的化合物。
• Indanyl-piperazine compounds
  申请人：De Nanteuil Guillaume

  公开号：US20060223830A1

  公开（公告）日：2006-10-05

  A compound selected from those of formula (I): wherein: R 3 represents a hydrogen atom, and R 1 and R 2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH 2 ) m —O-Ak-, —(CH 2 ) m —NR 4 -Ak-, —(CO)—NR 4 -Ak- and —(CH 2 ) m —NR 4 -(CO)—, m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R 4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK 1 antagonist.

  从公式（I）中选择的化合物：其中：R3代表氢原子，R1和R2与携带它们的碳原子一起形成苯、萘或喹啉环结构，每个环结构可选择地被取代，或R1代表氢原子，R2和R3与携带它们的碳原子一起形成苯、萘或喹啉环结构，每个环结构可选择地被取代，n代表1或2，-X-代表从-(CH2)m-O-Ak-、-(CH2)m-NR4-Ak-、-(CO)-NR4-Ak-和-(CH2)m-NR4-(CO)-中选择的基团，m代表1到6之间的整数，Ak代表可选择地取代的烷基链，R4代表氢原子或烷基基团，Ar代表芳基或杂环芳基基团，它的对映异构体、顺反异构体和与药用酸形成的加合物。含有这些化合物的医药产品在治疗需要血清素再摄取抑制剂和/或NK1拮抗剂的病症中有用。
• [EN] SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF<br/>[FR] DERIVE D'ACIDE ARYLALCANOIQUE SUBSTITUE ET SON UTILISATION
  申请人：ASAHI KASEI PHARMA CORP

  公开号：WO2005016862A1

  公开（公告）日：2005-02-24

  A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）。在该式中，Link代表一个由1至3个碳原子组成的饱和或不饱和直链烃链，芳环（E）中的C2至C6独立代表构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或者被Zx取代的碳原子，Zx代表由1至4个碳原子组成的饱和烷基基团等，Rs代表-D-Rx等，D代表单键、氧原子等，Rx代表由3至8个碳原子组成的饱和烷基基团等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子、由1至4个碳原子组成的低烷基基团等，或其盐。提供了一种具有抑制前列腺素产生和抑制白三烯产生作用的化合物。
• [EN] ANTIBIOTIC ADJUVANT COMPOUNDS<br/>[FR] COMPOSÉS D'ADJUVANT ANTIBIOTIQUE
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2021257173A1

  公开（公告）日：2021-12-23

  We report improved adjuvant compounds that have an aryl 2-aminoimidazole structure for macrolide potentiation against a virulent strain of gram-negative bacteria, AB5075. Compounds were discovered to retain significant adjuvant activity at 10 μM, lowering the minimum inhibitory concentration (MIC) of clarithromycin (CLR) from 8-fold to 128-fold or greater. 2-Aminoimidazole compounds linked to aryl groups via either an amide or urea linker showed significantly improved activity over control compounds.

  我们报告了一种改进的辅助化合物，其具有芳基2-氨基咪唑结构，可以增强大环内酯类抗生素对革兰氏阴性细菌AB5075的作用。发现这些化合物在10微摩尔浓度下仍保持显著的辅助活性，将克拉霉素（CLR）的最低抑制浓度（MIC）从8倍降低到128倍或更高。通过酰胺或脲连接物连接到芳基的2-氨基咪唑化合物显示出明显优于对照化合物的活性。
• FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS
  申请人：Appleyard Antony Nicholas

  公开号：US20130137630A1

  公开（公告）日：2013-05-30

  Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.

  描述了一种用于输液或直接注射的B型兰替生物抗生素液体胶体制剂，包括B型兰替生物抗生素或其盐，含有糖醇（如甘油）和/或糖类的等渗水溶液，以及可选的缓冲剂，其中用于输液或直接注射的最终制剂不含有可见颗粒。